MapLight Therapeutics (MPLT) CEO Kroeger Sells $595K of Stock

MapLight Therapeutics, Inc. Chief Executive Officer Christopher A. Kroeger sold 73,691 shares of company stock on October 15, 2026. According to a Form 4 filing with the SEC, the transaction was executed at a price of $8.08 per share, totaling roughly $595,423.

Following the sale, the CEO kept 1,195,909 shares, reducing his holding by about 5.8%. The stock closed at $8.02 on the day of the trade.

Other Institutional Activity in MapLight Therapeutics

Large outside shareholders held their ground in recent reporting periods. Novo Holdings A/S kept its stake at 3,686,622 shares valued at about $28.4 million. FCPM III Services B.V. maintained its holding of 3,226,400 shares worth about $24.8 million. Nan Fung Group Holdings Limited stayed put with 971,253 shares valued at approximately $7.5 million. 5AM Venture Management, LLC held 950,011 shares worth about $7.3 million. Sanofi kept its investment steady at 912,041 shares valued at about $7.0 million.

MapLight Therapeutics, Inc. Stock Down 3.9%

Shares recently traded around $7.71 as of October 17, 2026, sitting down about 3.9% since the insider sale. The stock trades near its 52-week low of $7.46.

Recent Earnings

The clinical-stage biopharmaceutical company reported a trailing twelve month loss with an EPS of -$6.25 and a return on equity of -111.5%. The next earnings report is scheduled for November 12, 2026.

Insider Buying and Selling at MapLight Therapeutics, Inc.

Several other executives also unloaded shares on October 15, 2026. Chief Medical Officer Erin Pennock Foff sold 15,355 shares at $8.08 each for a total value of $124,068. General Counsel Kristopher Hanson unloaded 9,020 shares at $8.08 apiece, totaling $72,882. Chief Scientific Officer James Woodruff Lillie sold 11,513 shares at $8.08 each for about $93,025. CAO and Interim CFO Jonathan Gillis parted with 10,167 shares at $8.08 apiece, totaling $82,149.

Analysts Set New Price Targets

Wall Street firms updated their views on the stock earlier in the year. Canaccord Genuity maintained a Buy rating on July 28, 2026, while lowering its target to $24.00 from $43.00. Morgan Stanley downgraded the stock to Equal-Weight with a $21.00 target on the same day. UBS lowered its rating to Neutral and cut its target to $13.00 on August 10, 2026. Needham maintained a Buy rating while lowering its target to $43.00 on August 31, 2026. Guggenheim initiated coverage with a Neutral rating on October 6, 2026.

About MapLight Therapeutics

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California. The firm focuses on developing treatments for patients suffering from debilitating central nervous system disorders.

Bottom Line

The executive sale highlights ongoing insider transactions at the biotech firm ahead of its upcoming earnings release. Investors will watch the November 12 report for further updates on the company's clinical pipeline.